WARRINGTON, Pa., April 18, 2016 /PRNewswire/ -- Discovery
Laboratories, Inc. (Nasdaq: DSCO), a biotechnology company focused
on developing aerosolized KL4 surfactant therapies for respiratory
diseases, today announced that it has changed its corporate name to
Windtree Therapeutics, Inc. and will trade under the Nasdaq symbol
"WINT" effective at market open on Tuesday, April 19, 2016.
"Today marks a new direction in the pursuit of our mission to
save and improve lives, beginning with the care of the most fragile
of patients – premature infants. As we look to the future, it
seems only fitting that recent changes in our leadership and
approach be coupled with a name and image most reflective of our
laser focus on respiratory disease, our commitment to patients, and
our determination to build a valuable venture," commented
Craig Fraser, Chief Executive
Officer. "We believe this rebranding effort will allow us to better
convey our focus and vision for the Company and for our products,
as well as reflect the fresh, new direction we are taking the
Company."
The name Windtree brings to mind a number of impressions that
resonate strongly within the respiratory space. "Wind"
signifies breath, air and motion, while reinforcing the ideas of
dynamism and change. "Tree" signifies the lungs, long life,
strength, and growth. The bringing together of the two words
is intended to capture the energy and character of this unique
Company as it begins an important new phase of its evolution.
The Company has also launched a new website, www.windtreetx.com,
which provides a clearer overview of its platform technologies and
vision for the future. The Company has also established a
presence on Twitter (@Windtreetx) and other social media
platforms. The Company intends to use these assets along with
traditional means of disclosure to increase transparency and
connectivity with investors and the medical community.
Windtree Therapeutics' Lead Program – AEROSURF®
Windtree's lead product candidate is AEROSURF®, a novel,
investigational drug/device product that combines the Company's
proprietary KL4 surfactant and aerosolization technologies.
AEROSURF is being developed to potentially reduce or eliminate the
need for endotracheal intubation and mechanical ventilation in the
treatment of premature infants with respiratory distress syndrome
(RDS). A phase 2b clinical trial in up to 240 premature
infants was initiated late last year to study AEROSURF in premature
infants 26 to 32-week gestational age receiving nasal continuous
positive airway pressure (nCPAP) for RDS, compared to infants
receiving nCPAP alone. The phase 2b trial is a global trial
with clinical sites in North
America, Europe and
Latin America. The Company remains
on track to complete enrollment in this trial by the end of 2016
and release top-line results in the first quarter of 2017.
About Windtree Therapeutics
Windtree Therapeutics, Inc. is a clinical-stage biotechnology
company focused on developing novel surfactant therapies for
respiratory diseases and other potential applications. Windtree
proprietary technology platform includes a synthetic,
peptide-containing surfactant (KL4 surfactant) that is
structurally similar to endogenous pulmonary surfactant — and novel
drug-delivery technologies being developed to enable noninvasive
administration of aerosolized KL4 surfactant. Windtree is
focused initially on improving the management of respiratory
distress syndrome (RDS) in premature infants and believes that its
proprietary technology may make it possible, over time, to develop
a pipeline of KL4 surfactant product candidates to address a
variety of respiratory diseases for which there are few or no
approved therapies.
For more information, please visit the Company's website at
www.windtreetx.com.
Forward-Looking Statements
To the extent that statements in this press release are not
strictly historical, all such statements are forward-looking, and
are made pursuant to the safe harbor provisions of the Private
Securities Litigation Reform Act of 1995. These
forward-looking statements are subject to certain risks and
uncertainties that could cause actual results to differ materially
from the statements made. Examples of such risks and
uncertainties, including those affecting Windtree Therapeutics'
ability successfully to secure required additional capital when
needed, complete its development programs, secure regulatory
approvals for its product candidates in the U.S. and abroad, and
realize the potential value and benefits of its RDS product
portfolio, are described in its filings with the Securities and
Exchange Commission, including its most recent reports on Forms
10-K, and any amendments thereto. Any forward-looking statement in
this release speaks only as of the date on which it is made.
Windtree Therapeutics assumes no obligation to update or revise any
forward-looking statements.
Logo - http://photos.prnewswire.com/prnh/20160415/356055LOGO
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/discovery-labs-changes-name-to-windtree-therapeutics-inc-nasdaq-wint-300252562.html
SOURCE Discovery Laboratories, Inc.
